Impact of re‐transurethral resection of bladder staging on risk stratification of high‐grade <scp>T1</scp> non‐muscle‐invasive bladder cancer across European Association of Urology 2021 risk groups
Residual T1 at re-TURB is strongly associated with adverse long-term oncological outcomes in BCG-treated T1HG NMIBC and markedly reduces the likelihood of statistical cure. High- and very high-risk patients with persistent T1 represent a biologically adverse subgroup in whom standard BCG may be insufficient.
Authors
- R. Pichler
- Élisabeth Grobet-Jeandin (ORCID: https://orcid.org/0000-0003-4602-8351)
- Pietro Scilipoti (ORCID: https://orcid.org/0009-0007-6126-9889)
- Ana Saiz
- Patricia Guerrero
- L Martínez (ORCID: https://orcid.org/0000-0001-8844-4893)
- A. Artiles Medina (ORCID: https://orcid.org/0000-0003-0930-0344)
- C. Mínguez Ojeda (ORCID: https://orcid.org/0000-0002-4188-3298)
- Tarek Ajami (ORCID: https://orcid.org/0000-0002-3505-8232)
- Valerio Santarelli (ORCID: https://orcid.org/0009-0009-9689-438X)
- Pablo Gajate (ORCID: https://orcid.org/0000-0001-5156-7080)
- Eduardo Albers Acosta (ORCID: https://orcid.org/0000-0002-0091-6209)
- Felipe Villacampa (ORCID: https://orcid.org/0000-0001-6779-6945)
- Júlia Aumatell (ORCID: https://orcid.org/0000-0001-7732-0596)
- Daniel A. González-Padilla
- Y Tsubono for the JPHC Study Group
- P. Del Olmo Duran
- José Daniel Subiela
- Franklin Anagua Melendres
- Karl H. Tully
- Oscar Buisan
- Andrea Gallioli
- Andrea Mari
- Almudena Coloma
- Marco Moschini
- Irene de la Parra
- Jorge Caño-Velasco
- David D'Andrea
- Ana Fernández-Mardomingo
- Francisco Javier Burgos Revilla
- Félix Guerrero-Ramos
- María de la Palma de la Estella Lucena
- Francesco Soria
- Mattia Longoni
- Aleksander Ślusarczyk
- Wojciech Krajewski
- Benjamin Pradere
- Luca Afferi
- Laura S Mertens
- Francesco Del Giudice
- Mario de Angelis
- Roberto Contieri
- Nils C H van Creij
- Simone Albisinni
Institutions
- University of Rome Tor Vergata (IT)
- Innsbruck Medical University (AT)
- Vita-Salute San Raffaele University (IT)
- Universidad de Alcalá (ES)
- Universität Innsbruck (AT)
- Instituto Cajal (ES)
- Medical University of Warsaw (PL)
- Policlinico Umberto I (IT)
- Hospital Universitario La Paz (ES)
- Bellvitge University Hospital (ES)
- The Netherlands Cancer Institute (NL)
- Universitätsklinik Marien Hospital Herne (DE)
- Comprehensive Cancer Center Vienna (AT)
- Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
- Hospital Universitario Rey Juan Carlos (ES)
- Hospital Universitario 12 De Octubre (ES)
- University Hospital of Geneva (CH)
- Hospital Clínic de Barcelona (ES)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Luzerner Kantonsspital (CH)
- Hospital Universitario de La Princesa (ES)
- Clinica Universidad de Navarra (ES)
- Hospital Universitario HM Sanchinarro (ES)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Puigvert Foundation (ES)
- Center for Special Minimally Invasive and Robotic Surgery (US)
- Roche (Spain) (ES)
- Hospital Universitario Ramón y Cajal (ES)
- University of Florence (IT)
- Geneva College (US)
- Medical University of Vienna (AT)
- Sapienza University of Rome (IT)
- Ruhr University Bochum (DE)
Publication Details
- Journal
- British Journal of Urology
- Published
- 2026-03-03
- DOI
- https://doi.org/10.1111/bju.70207
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00